School of Health and Social Development, Deakin Health Economics, Institute for Health Transformation, Deakin University, Geelong, Australia.
Institute for Management in Medicine and Health Sciences, University of Bayreuth, Bayreuth, Germany.
Appl Health Econ Health Policy. 2024 Jul;22(4):503-525. doi: 10.1007/s40258-024-00878-0. Epub 2024 Mar 30.
There has been an increase in model-based economic evaluations of interventions for dementia. The most recent systematic review of economic evaluations for dementia highlighted weaknesses in studies, including lack of justification for model assumptions and data inputs.
This study aimed to update the last published systematic review of model-based economic evaluations of interventions for dementia, including Alzheimer's disease, with a focus on any methodological improvements and quality assessment of the studies.
Systematic searches in eight databases, including PubMed, Cochrane, Embase, CINAHL, PsycINFO, EconLit, international HTA database, and the Tufts Cost-Effectiveness Analysis Registry were undertaken from February 2018 until August 2022. The quality of the included studies was assessed using the Philips checklist and the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 checklist. The findings were summarized through narrative analysis.
This review included 23 studies, comprising cost-utility analyses (87%), cost-benefit analyses (9%) and cost-effectiveness analyses (4%). The studies covered various interventions, including pharmacological (n = 10, 43%), non-pharmacological (n = 4, 17%), prevention (n = 4, 17%), diagnostic (n = 4, 17%) and integrated (n = 1, 4%) [diagnostics-pharmacologic] strategies. Markov transition models were commonly employed (65%), followed by decision trees (13%) and discrete-event simulation (9%). Several interventions from all categories were reported as being cost effective. The quality of reporting was suboptimal for the Methods and Results sections in almost all studies, although the majority of studies adequately addressed the decision problem, scope, and model-type selection in their economic evaluations. Regarding the quality of methodology, only a minority of studies addressed competing theories or clearly explained the rationale for model structure. Furthermore, few studies systematically identified key parameters or assessed data quality, and uncertainty was mostly addressed partially.
This review informs future research and resource allocation by providing insights into model-based economic evaluations for dementia interventions and highlighting areas for improvement.
基于模型的干预措施治疗痴呆症的经济评价呈增长趋势。最近对痴呆症经济评价的系统综述强调了研究中的弱点,包括模型假设和数据输入缺乏合理性。
本研究旨在更新最后一次发表的关于基于模型的痴呆症干预措施(包括阿尔茨海默病)经济评价的系统综述,重点关注研究方法的改进和质量评估。
从 2018 年 2 月至 2022 年 8 月,在 8 个数据库(包括 PubMed、Cochrane、Embase、CINAHL、PsycINFO、EconLit、国际卫生技术评估数据库和塔夫茨成本效益分析登记处)中进行了系统检索。使用飞利浦清单和健康经济评估报告标准(CHEERS)2022 清单评估纳入研究的质量。通过叙述性分析总结研究结果。
本综述包括 23 项研究,包括成本效用分析(87%)、成本效益分析(9%)和成本效果分析(4%)。研究涵盖了各种干预措施,包括药物治疗(n=10,43%)、非药物治疗(n=4,17%)、预防(n=4,17%)、诊断(n=4,17%)和综合(n=1,4%)[诊断-药物治疗]策略。Markov 转移模型(65%)最为常用,其次是决策树(13%)和离散事件模拟(9%)。所有类别中的多种干预措施均被报道为具有成本效益。几乎所有研究的方法和结果部分的报告质量都不理想,尽管大多数研究在其经济评价中充分解决了决策问题、范围和模型类型选择。关于方法学质量,只有少数研究涉及竞争理论或清楚地解释了模型结构的基本原理。此外,很少有研究系统地确定关键参数或评估数据质量,并且不确定性大多仅部分得到解决。
本综述通过提供有关痴呆症干预措施的基于模型的经济评价的见解,并强调需要改进的领域,为未来的研究和资源分配提供了信息。